TY - JOUR
T1 - Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients
AU - Masuyama, Keisuke
AU - Goto, Minoru
AU - Takeno, Sachio
AU - Ohta, Nobuo
AU - Okano, Mitsuhiro
AU - Kamijo, Atsushi
AU - Suzuki, Motohiko
AU - Terada, Tetsuya
AU - Sakurai, Daiju
AU - Horiguchi, Shigetoshi
AU - Honda, Kohei
AU - Matsune, Shoji
AU - Yamada, Takechiyo
AU - Sakashita, Masafumi
AU - Yuta, Atsushi
AU - Fuchiwaki, Takashi
AU - Miyanohara, Ikuyo
AU - Nakayama, Takeo
AU - Okamoto, Yoshitaka
AU - Fujieda, Shigeharu
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT.
AB - Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT.
KW - Allergic rhinitis
KW - Guideline
KW - Subcutaneous immunotherapy
KW - Sublingual immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84958058886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958058886&partnerID=8YFLogxK
U2 - 10.1016/j.anl.2015.08.015
DO - 10.1016/j.anl.2015.08.015
M3 - Article
AN - SCOPUS:84958058886
SN - 0385-8146
VL - 43
SP - 1
EP - 9
JO - Auris Nasus Larynx
JF - Auris Nasus Larynx
IS - 1
ER -
